15th Annual University of Pennsylvania conference on statistical issues in clinical trial/advances in time-to-event analyses in clinical trials (afternoon panel discussion)
Restricted accessResearch articleFirst published online October, 2024
15th Annual University of Pennsylvania conference on statistical issues in clinical trial/advances in time-to-event analyses in clinical trials (afternoon panel discussion)
BebuILachinJM. Optimal screening schedules for disease progression, with application to diabetic retinopathy. Biostat2018; 19: 1–13.
2.
NathanDBebuIHainsworthD, et al. Evidence-based screening frequency for retinopathy in type 1 diabetes. N Engl J Med2017; 376: 1507–1516.
3.
FinkelsteinDMSchoenfeldDA. Combining mortality and longitudinal measures in clinical trials. Stat Med1999; 18(11): 1341–1354.
4.
PocockSJAritiCACollierTJ, et al. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J2012; 33(2): 176–182.
5.
BebuILachinJM. Large sample inference for a composite analysis based on prioritized components. Biostat2016: 17: 178–187
6.
EvansSRRubinDFollmannD, et al. Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR). Clin Infect Dis2015; 61(5): 800–806.
7.
BebuILachinJM. Properties of composite time-to-first-event versus joint marginal analyses of multiple outcomes. Stat Med2018; 37(27): 3918–3930.
8.
FayMPBrittainEHShihJH, et al. Causal estimands and confidence intervals associated with Wilcoxon-Mann-Whitney tests in randomized experiments. Stat Med2018; 37(20): 2923–2937.
9.
MaoL. On causal estimation using U-statistics. Biometrika2018; 105(1): 215–220.
10.
BeigelJHTomashekKMDoddLE, et al. Remdesivir for the treatment of Covid-19—final report. N Engl J Med2020; 383(19): 1813–1826.
11.
FintziJBonnettTSweeneyDA, et al. Deconstructing the treatment effect of remdesivir in the adaptive coronavirus disease 2019 (COVID-19) treatment trial-1: implications for critical care resource utilization. Clin Infect Dis2022; 74(12): 2209–2217.
12.
MaoL. On restricted mean time in favor of treatment. Biometrics2023; 79(1): 61–72.
13.
FayMPShihJH. Weighted logrank tests for interval censored data when assessment times depend on treatment. Stat Med2012; 31(28): 3760–3772.
14.
EatonAAZaborEC. Analysis of composite endpoints with component-wise censoring in the presence of differential visit schedules. Stat Med2022; 41(9): 1599–1612.
15.
HernánMA. The hazards of hazard ratios. Epidemiology2010; 21(1): 13–15.
16.
VansteelandtSDukesOVan LanckerK, et al. Assumption-lean Cox regression. J Am Stat Assoc2022; 119(545): 475–484.
17.
WeiGSchaubelDE. Estimating cumulative treatment effects in the presence of nonproportional hazards. Biometrics2008; 64(3): 724–732.
18.
LawlessJFCookRJ. A new perspective on loss to follow-up in failure time and life history studies. Stat Med2019; 38(23): 4583–4610.
19.
AalenOOBorganØFekjærH. Covariate adjustment of event histories estimated from Markov chains: the additive approach. Biometrics2001; 57(4): 993–1001.
